Idoroenyi Amanam, MD, discusses real-world study of luspatercept in LR-MDS
In this video interview with Dr. Amanam, he discusses the results of an abstract presented at ASCO 2025 titled, “Real-world outcomes of patients
2025 ASCO
EHA 2025
B-ALL patients refractory to brexu-cel face poor survival outcomes
Relapse after treatment with the chimeric antigen receptor (CAR) T-cell therapy brexucabtagene autoleucel (brexu-cel) is associated with limited survival outcomes, “underscoring a need
EHA 2025
Pediatric-inspired Ph– ALL protocol reduces toxicity without improving survival
Researchers introduced a pediatric-inspired treatment protocol at their institution for patients with Philadelphia-negative (Ph–) acute lymphoblastic leukemia (ALL) and found that overall survival
EHA 2025
Post-CAR-T recovery of T cell, NK cell counts predicts long-term prognosis in B-ALL
Early recovery of specific T-cell counts and natural killer (NK) cell counts after CD19 chimeric antigen receptor (CAR)-T therapy can be used as
EHA 2025
Meetings / Conferences
News
Study supports recommendation that pregnancy be avoided in women taking ponatinib
A small study found that among pregnancies in which the mother was exposed to ponatinib, cases of Hirschsprung’s disease (HD) occurred. Paternal exposure
News
Study finds ropeginterferon alfa-2b is ‘superior’ 2nd-line treatment for essential thrombocythemia
A study compared second-line treatment options for essential thrombocythemia (ET) and found that ropeginterferon alfa-2b “outperformed” anagrelide in both efficacy and safety outcomes.
EHA 2025
Longer-term follow-up demonstrates efficacy of nemtabrutinib for refractory FL
Follow-up results from the BELLWAVE-003 study assessing nemtabrutinib in patients with hematologic malignancies showed continued antitumor activity and no new safety concerns with
EHA 2025
Meetings / Conferences
Myeloproliferative Neoplasms
Dr. Kuykendall from EHA 2025: ‘the research is as hot as the conference center’
Andrew Kuykendall, MD, SOHO Insider MPN podcast host, and assistant professor in the Department of Malignant Hematology at Moffitt Cancer Center, delivers live
EHA 2025
News
FELIX post-hoc data reinforce obe-cel durability
A post-hoc analysis found that the chimeric antigen receptor T-cell therapy obecabtagene autoleucel (obe-cel) produced durable remissions and maintained a favorable benefit-risk profile
Leukemia
Young Investigator Program
Dr. Gonzalez Lugo reflects on the SOHO YIP award
Meet Jesus Gonzalez Lugo, MD, an assistant professor of medicine at the University of Kansas and a 2024 SOHO Young Investigator Program (YIP)